Clinical trial
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary…
NCT00019786 · National Institutes of Health Clinical Center (CC), NIH · Completed
Key facts
| NCT number | NCT00019786 |
|---|---|
| Title | Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases |
| Official title | A Phase II Study of Isolated Hepatic Perfusion (IHP) With Melphalan for Metastatic Unresectable Cancers of the Liver |
| Lead sponsor | National Institutes of Health Clinical Center (CC), NIH |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Islet Cell Tumor, Liver Cancer, Metastatic Cancer, Neuroendocrine Carcinoma |
| Intervention type | Drug, Procedure |
| Interventions | isolated perfusion, melphalan, conventional surgery |
| Enrollment | 67 |
| Start date | Aug 1, 1999 |
| Completion | Jan 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 23, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: